Divis Laboratories Ltd
Divis Laboratories Ltd is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceutical ingredients with predominance in exports. It has a market presence in 95 countries and ~14,000 employees and is one of the leading pharmaceutical companies in the world.[1]
- Market Cap ₹ 89,926 Cr.
- Current Price ₹ 3,387
- High / Low ₹ 4,641 / 3,195
- Stock P/E 30.3
- Book Value ₹ 455
- Dividend Yield 0.89 %
- ROCE 35.1 %
- ROE 28.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 22.8% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 28.4%
Cons
- Stock is trading at 7.45 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,315 | 1,845 | 2,129 | 2,514 | 3,084 | 3,720 | 4,024 | 3,816 | 4,880 | 5,311 | 6,799 | 8,880 | 8,989 | |
809 | 1,149 | 1,306 | 1,492 | 1,914 | 2,314 | 2,582 | 2,558 | 3,028 | 3,491 | 3,971 | 5,000 | 5,346 | |
Operating Profit | 505 | 696 | 823 | 1,022 | 1,170 | 1,406 | 1,441 | 1,258 | 1,851 | 1,820 | 2,828 | 3,880 | 3,643 |
OPM % | 38% | 38% | 39% | 41% | 38% | 38% | 36% | 33% | 38% | 34% | 42% | 44% | 41% |
29 | 66 | 49 | 81 | 36 | 92 | 73 | 106 | 155 | 187 | 57 | 109 | 236 | |
Interest | 2 | 5 | 3 | 3 | 3 | 4 | 3 | 2 | 5 | 7 | 2 | 2 | 0 |
Depreciation | 53 | 62 | 77 | 92 | 136 | 118 | 123 | 142 | 169 | 186 | 255 | 311 | 329 |
Profit before tax | 479 | 695 | 792 | 1,009 | 1,067 | 1,375 | 1,388 | 1,219 | 1,833 | 1,813 | 2,628 | 3,677 | 3,549 |
Tax % | 9% | 21% | 23% | 22% | 21% | 19% | 24% | 29% | 27% | 24% | 26% | 20% | |
Net Profit | 436 | 546 | 611 | 792 | 847 | 1,111 | 1,053 | 870 | 1,333 | 1,373 | 1,955 | 2,949 | 2,969 |
EPS in Rs | 16.42 | 20.56 | 23.03 | 29.82 | 31.90 | 41.84 | 39.68 | 32.76 | 50.20 | 51.71 | 73.63 | 111.07 | 111.82 |
Dividend Payout % | 30% | 32% | 33% | 34% | 31% | 24% | 25% | 31% | 32% | 31% | 27% | 27% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 17% |
3 Years: | 22% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 23% |
3 Years: | 31% |
TTM: | 41% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 25% |
3 Years: | 20% |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | 23% |
5 Years: | 22% |
3 Years: | 24% |
Last Year: | 28% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
27 | 27 | 27 | 27 | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | |
Reserves | 1,802 | 2,148 | 2,527 | 3,008 | 3,535 | 4,304 | 5,356 | 5,907 | 6,920 | 7,264 | 9,218 | 11,638 | 12,022 |
23 | 55 | 33 | 18 | 27 | 42 | 36 | 63 | 106 | 34 | 0 | 0 | 0 | |
457 | 573 | 610 | 731 | 886 | 566 | 765 | 785 | 961 | 1,164 | 1,452 | 1,617 | 1,365 | |
Total Liabilities | 2,308 | 2,803 | 3,196 | 3,784 | 4,475 | 4,965 | 6,210 | 6,808 | 8,040 | 8,514 | 10,724 | 13,308 | 13,440 |
590 | 738 | 908 | 1,222 | 1,309 | 1,439 | 1,559 | 1,996 | 2,087 | 2,776 | 3,699 | 4,321 | 4,328 | |
CWIP | 104 | 182 | 303 | 144 | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 542 |
Investments | 528 | 480 | 411 | 505 | 736 | 813 | 1,639 | 1,897 | 1,953 | 979 | 7 | 79 | 82 |
1,086 | 1,403 | 1,573 | 1,913 | 2,212 | 2,450 | 2,568 | 2,795 | 3,508 | 3,839 | 6,307 | 8,438 | 8,488 | |
Total Assets | 2,308 | 2,803 | 3,196 | 3,784 | 4,475 | 4,965 | 6,210 | 6,808 | 8,040 | 8,514 | 10,724 | 13,308 | 13,440 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
326 | 334 | 483 | 558 | 822 | 1,036 | 1,149 | 765 | 964 | 1,208 | 1,947 | 1,910 | |
-222 | -204 | -254 | -305 | -521 | -411 | -1,137 | -476 | -684 | -81 | 75 | -2,195 | |
-104 | -131 | -231 | -248 | -303 | -630 | 3 | -314 | -246 | -1,091 | -34 | -532 | |
Net Cash Flow | -0 | -1 | -2 | 5 | -1 | -5 | 15 | -25 | 34 | 36 | 1,988 | -817 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 109 | 106 | 96 | 115 | 97 | 95 | 91 | 106 | 96 | 105 | 94 | 106 |
Inventory Days | 374 | 307 | 369 | 355 | 335 | 284 | 291 | 311 | 324 | 299 | 322 | 316 |
Days Payable | 83 | 74 | 72 | 59 | 67 | 56 | 103 | 98 | 94 | 99 | 118 | 92 |
Cash Conversion Cycle | 399 | 339 | 392 | 411 | 365 | 323 | 280 | 319 | 325 | 305 | 298 | 330 |
Working Capital Days | 167 | 149 | 156 | 165 | 149 | 169 | 156 | 191 | 181 | 186 | 155 | 178 |
ROCE % | 28% | 34% | 33% | 36% | 32% | 35% | 28% | 21% | 28% | 24% | 32% | 35% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
25 Jan - Schedule of earnings conference call for Q3FY23 to be held on February 03, 2023.
- Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022. 23 Jan
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jan - Depositories and Participants) Regulations, 2018, we herewith submit certificate for the quarter ended December 31, 2022 received from M/s. KFin Technologies Limited, Registrar & Share …
- Closure of Trading Window 24 Dec 2022
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Dec 2022 - Of notice given to shareholders in respect of transfer of equity shares to IEPF Account by Newspaper advertisement
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from nse
-
Financial Year 2010
from bse
-
Financial Year 2009
from nse
Concalls
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Mar 2017TranscriptPPT
Product Portfolio
The company is engaged in production of leading generic APIs, Nutraceutical ingredients and custom synthesis of APIs and intermediates for global companies.
It has a product portfolio of 122 products across various therapeutic areas.[1]
The company derives ~47% of total revenues from top 5 products. Naproxen (an anti-inflammatory drug) contributed ~18% of total sales during FY20. The company is one of the leading suppliers of this drug.[2]